---
title: Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study
nct_id: NCT01793181
overall_status: COMPLETED
sponsor: St. Erik Eye Hospital
study_type: OBSERVATIONAL
primary_condition: Vitamin d Deficiency
countries: Sweden
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01793181.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01793181"
ct_last_update_post_date: 2016-11-25
last_seen_at: "2026-05-12T07:16:29.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study

**NCT ID:** [NCT01793181](https://clinicaltrials.gov/study/NCT01793181)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 216
- **Lead Sponsor:** St. Erik Eye Hospital
- **Conditions:** Vitamin d Deficiency, Central Retinal Vein Occlusion
- **Start Date:** 2013-01
- **Completion Date:** 2014-11
- **CT.gov Last Update:** 2016-11-25

## Brief Summary

Retinal vein occlusion (RVO) is a common vascular disease of the eye. Studies have shown that the risk of venous thrombosis is higher in winter so even concerning RVO. Studies have shown a possible link between sun exposure and venous thrombosis. Vitamin D levels have been shown to have a similar seasonal variation, with a peak occurring in the summer. The primary source of vitamin D is from sunlight when ultraviolet B (UVB) radiation penetrates the skin and converts 7-dehydrocholesterol to 25-hydroxycholecalciferol vitamin D3 (25-OHVitD) via previtamin D. In Stockholm situated at latitude 59˚ 20΄ North, it is not possible to synthesize vitamin D at sufficient levels in winter and the exposure time required to reach a standard dose is impractical from at least October through March.

The aim of the study is to evaluate vitamin D levels in central retinal vein occlusion (CRVO) patients and compare them with the vitamin D levels in randomly selected control patients matched for age and month of disease onset. This is to evaluate whether vitamin D deficiency may be a risk factor in the onset of CRVO.

The hypothesis of the study is that patients with CRVO have lower levels of vitamin d than matched controls.

## Detailed Description

The study will last one year and is expected to include 120 patients with RVO and 120 control patients. The first 10 RVO patients visiting St. Erik's Eye Hospital with disease duration of maximum 3 months will be included in the study each month. The control patients will be chosen randomly by the Central Bureau of Statistics and matched for age and gender according to disease distribution known from previous studies. The control group will receive a letter with information of the study, informed consent form and details about the blood sampling procedure. Every month 50 patients in the control group will be invited to participate in the study. Only the first 10 control subjects will be included in the study. Each month a blood sample will be taken from 10 patients with RVO and 10 subjects in the control group. All the subjects will only have one blood sample taken during the study. Blood will be analyzed to measure the vitamin D level. Vitamin D levels will be compared at the end of the study between groups and evaluated according to the time of year for sampling. All the blood sampling will be done by the laboratory at Karolinska University Hospital. Participation in the study is completely voluntary. The details of the study has been reviewed and approved by the Ethics Committee.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 90 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Newly diagnosed central retinal vein occlusion (3 months)

Exclusion Criteria:

\-
```

## Arms

- **CRVO patients** — Patients with a newly diagnosed CRVO. Maximum duration 3 months.
- **Control patients** — Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden

## Primary Outcomes

- **Vitamin D levels** _(time frame: one year)_

## Locations (1)

- St Eriks Eye Hospital, Stockholm, Stockholm County, Sweden

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.st eriks eye hospital|stockholm|stockholm county|sweden` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01793181.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01793181*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*